The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages

  Welsh, James W ^a   Mahadevan, Daruka ^b   Ellsworth, Ron ^b   Cooke, Laurence ^c   Bearss, David ^d   Stea, Baldassarre ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d SuperGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE H2AX; MP 470; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAD51 PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; MP470; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RADIOSENSITIZATION; SURVIVAL TIME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BRAIN TUMOR; CELL PROLIFERATION; COMET ASSAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; RADIATION DOSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMET ASSAY; DNA BREAKS, DOUBLE-STRANDED; GLIOBLASTOMA; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIMIDINES; RADIATION TOLERANCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74549159014     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-69     Document Type: Article

References (22)

1. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery: BTSG 72-01. N England J Med 1980, 1323-1327.
2. Lee SW, Fraass BA, Marsh LH, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999, 43:79-88.
3. Green S, Shapiro W, Burger P, Selker R, Van Gilder J, Saris S. A randomized trial of interstitial radiotherapy (RT) boost for newly diagnosed malignant glioma: Brain Tumor Cooperative Group (BTCG) trial 8701. Proc Ann Meet Am Soc Clin Oncol 1994, 13:174.
4. Fan S, Ma YX, Gao M, Yuan R-Q, Meng Q, Goldberg ID, Rosen EM. The multisubstrate adapter gab1 regulates hepatocyte growth factor (scatter factor)-c-met signaling for cell survival and DNA repair. Mol Cell Biol 2001, 21:4968-4984.
5. Fan S, Ma YX, Wang J-A, Yuan R-Q, Meng Q, Laterra JJ, Goldberg ID, Rosen EM. The cytokine scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidylinositol 3' kinase. Oncogene 2000, 19:2212-2223.
6. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002, 109:863-867.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande GFW. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.
8. Maulik G, Shrikhande A, KijimaT Ma PC, MorrisonPT RS. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002, 13:41-59.
9. Toschi L, Janne PA. Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer. Clin Cancer Res 2008, 14:5941-5946.
10. Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met Pathway Potentiates Glioblastoma Responses to γ-Radiation. Clin Cancer Res 2005, 11:4479.
11. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007, 26:3909-3919.
12. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007, 13:84-88.
13. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004, 26:249-261.
14. Secrist JP, Burns LA, Karnitz L, Koretzky GA, Abraham RT. Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events. J Biol Chem 1993, 268:5886-5893.
15. Graziani A, Gramaglia D, Cantley LC, Comoglio PM. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 1991, 266:22087-22090.
16. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Progress in Neurobiology 2006, 173-189.
17. Tarsounas M, Davies AA, West SC. RAD51 localization and activation following DNA damage. Philos Trans R Soc Lond B Biol Sci 2004, 359:87-93.
18. Kawabata M, Kawabata T, Nishibori M. Role of recA/RAD51 family proteins in mammals. Acta Med Okayama 2005, 59:1-9.
19. Kumar R, Welsh J, Nagle RB, Green S, Stea B. Association between Rad-51 Levels and Survival in Patients With Glioblastoma Multiforme Treated With Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 2007, 69:S63-S64.
20. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF. Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials. J Natl Cancer Inst 1993, 85:704-710.
21. Welsh JW, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, Kwong E, Stea B. GliaSite Brachytherapy Boost as Part of Initial Treatment of Glioblastoma Multiforme: A Retrospective Multi-Institutional Pilot Study. International Journal of Radiation Oncology*Biology*Physics 2007, 68:159-165.
22. Joshi R, Kanekal S, Inloes R, Grand CL, Liu X, Vankayalapati H, Bernard L, Jones R, Bearss DJ, Redkar S. MP470.HCl, a Potent Suppressor of Rad51, Improves Bioavailability and Tolerability. AACR-NCI-EORTC 2007,